<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002258</url>
  </required_header>
  <id_info>
    <org_study_id>080A</org_study_id>
    <secondary_id>B104</secondary_id>
    <nct_id>NCT00002258</nct_id>
  </id_info>
  <brief_title>A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia</brief_title>
  <official_title>A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine the safety, tolerability and maximum tolerated dose of SDZ ILE 964 administered&#xD;
      by daily subcutaneous injections in patients infected with human immunodeficiency virus (HIV)&#xD;
      who have cytopenias (low blood cell counts). To obtain information about the biologic effects&#xD;
      of SDZ ILE 964 administration in improving blood counts in HIV-infected patients. To obtain&#xD;
      information about the effects of SDZ ILE-964 administration on both parameters of HIV&#xD;
      replication and on residual immunologic function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <condition>Cytopenias</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-3</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV seropositivity by Western blot.&#xD;
&#xD;
          -  Advanced ARC or AIDS as defined by CDC.&#xD;
&#xD;
          -  Cytopenia defined as total peripheral leukocyte count of &lt; 3,000 cells/mm3 or platelet&#xD;
             count of &lt; 100,000 cells/mm3 or serum hemoglobin &lt; 10 g/dl.&#xD;
&#xD;
          -  Anticipated life expectancy = or &gt; 6 months.&#xD;
&#xD;
          -  Ambulatory.&#xD;
&#xD;
          -  Willing to sign informed consent.&#xD;
&#xD;
          -  Willing to forego use of any other investigational therapies except ddI.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed &gt; 2 weeks prior to study entry:&#xD;
&#xD;
          -  zidovudine.&#xD;
&#xD;
          -  Allowed &gt; 4 weeks prior to study entry:&#xD;
&#xD;
          -  systemic cytotoxic chemotherapy; investigational drugs; medications known to be&#xD;
             myelosuppressive as ganciclovir, trimethoprim/sulfamethoxazole or dapsone.&#xD;
&#xD;
          -  Allowed &gt; 6 weeks prior to study entry:&#xD;
&#xD;
          -  other hemopoietic growth factor treatment as GM-CSF, EPO.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Active opportunistic infection.&#xD;
&#xD;
          -  Symptoms of CNS disease referable to HIV infection.&#xD;
&#xD;
          -  Dementia or altered mental status that would prohibit giving and understanding&#xD;
             informed consent.&#xD;
&#xD;
        Systemic chemotherapy.&#xD;
&#xD;
          -  Investigational therapies other than ddI.&#xD;
&#xD;
          -  Medications with known myelosuppressive effects such as ganciclovir,&#xD;
             trimethoprim/sulfamethoxazole or dapsone or AZT.&#xD;
&#xD;
          -  Other hematopoietic growth factor treatments as GM-CSF, G-CSF, or EPO.&#xD;
&#xD;
        Prophylactic therapy for pneumocystis or oral thrush.&#xD;
&#xD;
          -  ddI.&#xD;
&#xD;
          -  Corticosteroids or topical corticosteroid creams.&#xD;
&#xD;
        Patients may not have:&#xD;
&#xD;
          -  Life expectancy &lt; 6 months.&#xD;
&#xD;
          -  Active drug or alcohol abuse.&#xD;
&#xD;
          -  Active opportunistic infections.&#xD;
&#xD;
          -  Treatment with any other investigational drugs except ddI within 4 weeks of study&#xD;
             entry.&#xD;
&#xD;
          -  Dementia or altered mental state that prohibits giving informed consent.&#xD;
&#xD;
          -  Symptoms of CNS disease referable to HIV infection.&#xD;
&#xD;
          -  Major surgery within 4 weeks of study entry.&#xD;
&#xD;
          -  History of major pulmonary or cardiac disease.&#xD;
&#xD;
          -  History of any prior malignancy other than Kaposi's sarcoma or noninvasive&#xD;
             subcutaneous carcinoma.&#xD;
&#xD;
          -  Documented allergic disorder such as asthma, history of anaphylaxis, atopy, serum&#xD;
             sickness, or bronchospasm.&#xD;
&#xD;
        Not allowed within 2 weeks prior to study entry:&#xD;
&#xD;
          -  zidovudine (AZT).&#xD;
&#xD;
          -  Not allowed within 4 weeks prior to study entry:&#xD;
&#xD;
          -  systemic cytotoxic chemotherapy; investigational drugs other than ddI; medications&#xD;
             known to be myelosuppressive as ganciclovir, trimethoprim/sulfamethoxazole or dapsone.&#xD;
&#xD;
          -  Not allowed within 6 weeks prior to study entry:&#xD;
&#xD;
          -  other hematopoietic growth factor treatment as GM-CSC, G-CSF, EPO.&#xD;
&#xD;
        Radiation therapy or major surgery within 4 weeks of study entry.&#xD;
&#xD;
        Active drug or alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>New England Deaconess Hosp</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Scadden DT, Levine JD, Bresnahan J, Gere J, McGrath J, Wang Z, Resta DJ, Young D, Hammer SM. In vivo effects of interleukin 3 in HIV type 1-infected patients with cytopenia. AIDS Res Hum Retroviruses. 1995 Jun;11(6):731-40. doi: 10.1089/aid.1995.11.731.</citation>
    <PMID>7576933</PMID>
  </reference>
  <reference>
    <citation>Levine AM, Li P, Cheung T, Tulpule A, Von Roenn J, Nathwani BN, Ratner L. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):444-50. doi: 10.1097/00126334-200008150-00009.</citation>
    <PMID>11035615</PMID>
  </reference>
  <verification_date>November 1992</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Interleukin-3</keyword>
  <keyword>Recombinant Proteins</keyword>
  <keyword>Leukopenia</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Thrombocytopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Leukopenia</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

